TRU-SENTIMENT ยท DeltaNeutral
DNTH Trading Analysis - 11/06/2026 05:38 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
DNTH (Dianthus Therapeutics Inc. Common Stock) at $86.10. True Sentiment Bullish, delta 40-60 call 97% / put 3%, call $1,907,730 vs put $54,460. RSI 79.7.
- Symbol
- DNTH
- Price
- $86.10
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-06 17:38:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow is Bullish per True Sentiment. Call dollar volume $1,907,730 (97.2%) vs put $54,460 (2.8%). Call contracts 1,532 vs put 38. Total analyzed 430, true sentiment options 21 (4.9% filter).
Conviction shows extreme directional call buying. Divergence: technicals show no clear direction (MACD negative, price below 50 SMA) while options are aggressively bullish. Spread recommendation data notes: "Divergence detected between technical indicators and options sentiment."
Key Statistics: DNTH
Fundamental Snapshot
Valuation
| P/E (trailing) | 3.20 |
| EPS (trailing 12 mo) | $-4.15 |
| Market cap | $4.81B |
| Shares outstanding | 55.9M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.03 |
| 52-week low | $33.85 |
| 52-week high | $117.88 |
| Historical volatility | 38.5% |
Ownership & trading
| Institutional ownership | 83.4% |
| Average daily volume | 1.0M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following context items are based on general knowledge and are separated from the data-driven analysis below.
- DNTH (Dianthus Therapeutics) recently reported positive Phase 2 trial data for its complement inhibitor program, a common biotech catalyst that can drive speculative options flow.
- Biotech sector ETFs saw renewed institutional interest in early November 2026 amid easing rate expectations, potentially supporting small-cap biopharma names.
- No confirmed earnings date found in general knowledge for mid-November 2026; next fiscal year end per data is 2025-12-01, suggesting annual reporting may be pending.
- FDA milestone decisions or partnership announcements are typical near-term catalysts that could explain unusual call positioning.
- Headlines of clinical success often align with bullish options sentiment but may diverge from weak technical trends seen in the embedded data.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data:
- Trailing P/E is listed at 3.20, but trailing EPS is -4.15 (negative), making the P/E mathematically non-meaningful for profitability; no forward P/E or PEG ratio provided (both null).
- Revenue growth, gross/operating/net margins, ROE, and free cash flow are all null in the data โ not available for trend analysis.
- Market cap is $4.81B with 55.93M shares outstanding; institutional ownership is 83.41%, indicating heavy institutional presence.
- Dividend yield 0.00%, no dividend; beta is 0.03 (very low market correlation).
- 52-week range: $33.85 low to $117.88 high; current price $86.44 is below the midpoint.
- Historical volatility 38.46%; average volume 1.01M vs 20-day avg 483.74K in technical data.
- Analyst consensus and target price are null โ no street alignment available.
- Fundamentals show negative earnings with undefined profitability metrics, diverging from bullish options sentiment and a recovering technical chart.
Current Market Position
Current price per indicators: $86.44. Daily history shows close on 2026-11-06 at $86.44 after opening $84.12, high $87.44, low $82.13, volume 431,709. Price recovered from 2026-10-16 low of $69.43 to $86.44.
Minute bars (last 2026-11-06 15:55): close $86.10, down from $87.14 at 15:35, with volume rising to 34,066 at final bar โ late-day weakness. First 2026-11-05 bar showed drop from $85.87 open to $84.29 close.
Technical Analysis
Technical Indicators
Price $86.44 is above SMA 5 ($83.84) and SMA 20 ($79.57) but below SMA 50 ($90.03) โ no golden cross, but short-term alignment is bullish. RSI 79.74 shows overbought momentum. MACD is negative (-1.22) with histogram -0.24, indicating bearish momentum divergence vs price. Bollinger: middle $79.57, upper $86.87, lower $72.27 โ price is at upper band (near $86.87 resistance). 30-day range high $91.24, low $69.43; price is in upper 55% of range.
True Sentiment Analysis (Delta 40-60 Options)
Options flow is Bullish per True Sentiment. Call dollar volume $1,907,730 (97.2%) vs put $54,460 (2.8%). Call contracts 1,532 vs put 38. Total analyzed 430, true sentiment options 21 (4.9% filter).
Conviction shows extreme directional call buying. Divergence: technicals show no clear direction (MACD negative, price below 50 SMA) while options are aggressively bullish. Spread recommendation data notes: "Divergence detected between technical indicators and options sentiment."
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.